Novo Nordisk A/S
Novo Nordisk A/S (NVO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NVO · as of Sep 30, 2024
Ownership Breakdown
1,855
Institutional Holders
▼ 63 vs Q2
$39.68B
Total Inst. Value
▼ $8.21B vs Q2
4.44B
Shares Outstanding
freeFloat 71.70%
335.25M
13F Shares Held
▼ 480,900 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NVO largest shareholders · institutional ownership
Q3 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JENNISON ASSOCIATES LLC pharmaceutical preparations | 20.20M | 45.35% | 45.35% | $2.40T | Nov 8, 2024 | ▼ 1.02M |
FMR LLC pharmaceutical preparations | 17.93M | 40.26% | 40.26% | $2.14T | Nov 13, 2024 | ▼ 1.56M |
MORGAN STANLEY pharmaceutical preparations | 14.37M | 32.25% | 32.25% | $1.71T | May 14, 2025 | ▼ 245.5K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 14.33M | 32.17% | 32.17% | $1.71T | Nov 14, 2024 | ▲ 137.1K |
FISHER ASSET MANAGEMENT, LLC pharmaceutical preparations | 13.31M | 29.88% | 29.88% | $1.58T | Nov 12, 2024 | ▼ 65.2K |
FAYEZ SAROFIM & CO pharmaceutical preparations | 12.22M | 27.43% | 27.43% | $1.45T | Nov 14, 2024 | ▼ 335.0K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 9.58M | 21.52% | 21.52% | $1.14T | Nov 14, 2024 | ▲ 79.7K |
FOLKETRYGDFONDET pharmaceutical preparations | 8.86M | 19.90% | 19.90% | $1.06T | Nov 13, 2024 | ▲ 24.9K |
LOOMIS SAYLES & CO L P pharmaceutical preparations | 8.62M | 19.36% | 19.36% | $1.03T | Nov 13, 2024 | ▼ 273.5K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 8.19M | 18.39% | 18.39% | $975.10B | Nov 13, 2024 | ▼ 976.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2024 vs prior quarter
Q3 2024
26
Increased
+10.05M shares1
New Positions
first time holders20
Decreased
−6.17M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.88M
+10.05M / −6.17M
Net new holders
+7
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NVO insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Novo Nordisk A/S (NVO) is primarily owned by institutional investors, who hold approximately 7.5% of total shares outstanding. Company insiders own approximately 28.30%, while retail and public investors account for the remaining 64.16%.
The largest institutional shareholder of Novo Nordisk A/S is JENNISON ASSOCIATES LLC, holding approximately 20.20 million shares — equal to 45.35% of outstanding shares — as of September 30, 2024.
A total of 1,855 institutional investors currently hold NVO stock, with a combined institutional value of approximately $39.68 billion as of the most recent 13F filing period.
Frequently asked questions
NVO ownershipNovo Nordisk A/S (NVO) is primarily owned by institutional investors, who hold approximately 7.5% of shares. The largest shareholder is JENNISON ASSOCIATES LLC with a 45.35% stake. Company insiders hold 28.30%. Data sourced from SEC Form 13F as of September 30, 2024.